Stock MDGL MADRIGAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Real-time Estimate Cboe BZX
Other stock markets
 10:47:49 2024-06-03 am EDT 		5-day change 1st Jan Change
241 USD +2.06% Intraday chart for Madrigal Pharmaceuticals, Inc. +8.55% +4.75%
May. 19 Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
May. 19 Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing
MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating
MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating
MT
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective
MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing
MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating
MT
Madrigal commences $500 million public offering of common stock
RE
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating
MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating
MT
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating
MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating
MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating
MT
B. Riley Upgrades Madrigal Pharmaceuticals to Neutral From Sell After FDA Approval of Rezdiffra, Raises PT to $270 From $155
MT
HC Wainwright Adjusts Madrigal Pharmaceuticals' Price Target to $405 From $275, Maintains Buy Rating
MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $320 From $300, Maintains Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. News Madrigal Pharmaceuticals, Inc.
  5. Analyst Reco.